The delayed approval and price setting of Novartis Pharma’s Zolgensma (onasemnogene abeparvovec), a gene therapy for spinal muscular atrophy (SMA) listed in May, has raised questions about how the sakigake designation system should be operated. Despite being designated for the…
HOME > ACADEMIA
ACADEMIA
- TMDU, Tokyo Govt Join Hands for Open Innovation in Drug Discovery, Healthcare
July 18, 2019
- Virologist Expresses Concern over Spread of Resistant Flu Viruses to Xofluza
July 17, 2019
- Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
- NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
- Gynecologist Stresses Urgent Need to Resume HPV Vaccinations, Cites Age Disparity in Cervical Cancer Risk
July 10, 2019
- Scientific Societies Compile Japan’s First Pharmacotherapy Guidelines for Elderly Cancer Patients
May 23, 2019
- Univ. of Tokyo, 3H to Start Matching Program for Rare Disease R&D
May 21, 2019
- Kobe Univ. Aims to Become APEC “Center of Excellence”; Could Promote Stronger Japanese Role in Regulatory Harmonization
May 17, 2019
- Treatment with Corticosteroids Strongly Recommended for Sclerosing Cholangitis: New Guidelines
May 9, 2019
- Risk of Relapse Will Be Challenge for CAR-T Cell Therapy: Immunologist
May 8, 2019
- Niigata Univ., Eisai Team Up to Develop Pancreatic Cancer Drug Using Highly Absorbed Peptide
May 7, 2019
- Revised Hypertension Treatment Guidelines Set Stricter Blood Pressure Reduction Target
April 23, 2019
- Nobel Laureate Honjo Says Rewards for Opdivo Patent Too Small
April 12, 2019
- Xofluza Shouldn’t Be Used Alone for Hong Kong Flu: Specialist
April 8, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
- Discuss Biosimilar Pricing Separate from High-Cost Medical Expense Benefits: Prof.
March 20, 2019
- NCNP to Set Up New Council to Accelerate Clinical Development of Neuromuscular Disorder Treatments
March 18, 2019
- Feburic Prevents Cerebral, Cardiorenovascular Events: Japan Multicenter Study
March 13, 2019
- Investigators Calling Off Trials on First Hyperlactacidemia Drug with No Significant Improvement Shown
February 28, 2019
- Keio Researchers Start Studying ReQuip for ALS after iPS Screening
February 25, 2019
ページ
When Jiho surveyed drug makers on the non-sales criteria they use to evaluate reps’ performance, it received a variety of…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…